Neurologic immune related adverse events (irAEs) in patients with metastatic solid tumors treated with immune checkpoint inhibitors: a single institution retrospective analysis

被引：0
|
作者：
Malani, Rachna [1 ]
Haggiagi, Aya [2 ]
Holder, Jenessa [1 ]
Shames, Yelena [1 ]
Briggs, Samuel [1 ]
Callahan, Margaret [1 ]
Santomasso, Bianca [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering, New York, NY USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
N6.001
引用
收藏
页数：2
相关论文
共 50 条
  • [1] THE DEVELOPMENT OF NEUROLOGIC IMMUNE RELATED ADVERSE EVENTS (irAEs) IN PATIENTS WITH METASTATIC SOLID TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A SINGLE INSTITUTION RETROSPECTIVE ANALYSIS
    Malani, Rachna
    Haggiagi, Aya
    Holder, Jenessa
    Shames, Yelena
    Briggs, Samuel
    Santomasso, Bianca
    Callahan, Margaret
    NEURO-ONCOLOGY, 2017, 19 : 168 - 168
  • [2] Neurotoxicity in patients with metastatic solid tumors treated with immune checkpoint inhibitors: a single institution retrospective analysis
    Santomasso, Bianca
    Malani, Rachna
    Haggiagi, Aya
    Holder, Jenessa
    Shames, Yelena
    Briggs, Samuel
    Callahan, Margaret
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [3] Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.
    Santomasso, Bianca
    Haggiagi, Aya
    Malani, Rachna
    Maher, Colleen Anne
    Holder, Jenessa N.
    Shames, Yelena
    Wilcox, Jessica
    Flynn, Jessica
    Briggs, Samuel
    Panageas, Katherine
    Callahan, Margaret K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
    Daban, A.
    Gonnin, C.
    Phan, L.
    Saldmann, A.
    Granier, C.
    Lillo-Lelouet, A.
    Le Beller, C.
    Pouchot, J.
    Weiss, L.
    Tartour, E.
    Fabre, E.
    Medioni, J.
    Oudard, S.
    Vano, Y. A.
    Dragon-Durey, M. A.
    Simonaggio, A.
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [5] Immune-related adverse events (IrAEs) in patients receiving immune checkpoint inhibitors
    Ferrarini, Alessia
    Benfaremo, Devis
    Rossetti, Giulia
    Morgese, Francesca
    Pomponio, Giovanni
    Berardi, Rossana
    Gabrielli, Armando
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [6] Immune-related adverse events (irAEs) and survival in solid tumors treated with immune checkpoint inhibitors (ICIs): A systematic review and meta-analysis.
    Grizzi, Giulia
    Petrelli, Fausto
    Ghidini, Michele
    Ghidini, Antonio
    Ratti, Margherita
    Panni, Stefano
    Cabiddu, Mary
    Ghilardi, Mara
    Borgonovo, Karen
    Parati, Maria Chiara
    Barni, Sandro
    Tomasello, Gianluca
    Passalacqua, Rodolfo
    Berruti, Alfredo
    Brighenti, Matteo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience
    Virik, K.
    Basulaiman, B.
    Robinson, A.
    Hopman, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S868 - S868
  • [8] Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs).
    Morehouse, Chris
    Abdullah, Shaad Essa
    Gao, Chen
    Dar, Mohammed M.
    Ranade, Koustubh
    Higgs, Brandon W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors
    Ornstein, Moshe C.
    Calabrese, Cassandra
    Wood, Laura S.
    Kirchner, Elizabeth
    Profusek, Pamela
    Allman, Kimberly D.
    Martin, Allison
    Kontzias, Arstolos
    Grivas, Petros
    Garcia, Jorge A.
    Calabrese, Leonard H.
    Rini, Brian, I
    CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : 177 - 182
  • [10] Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs)
    Durbin, Sienna
    Zubiri, Leyre
    Perlman, Katherine
    Molina, Gabriel
    Jacoby, Ted
    Shah, Nishi
    Reynolds, Kerry Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345